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Abstract
Cancer biomarkers (CB) are biomolecules produced either by the tumor cells or by other
cells of the body in response to the tumor. Every cell type has its unique molecular signature
and identifiable characteristics such as levels or activities of myriad of genes, proteins, or
other molecular features; therefore, biomarkers can facilitate the molecular definition of
cancer. Our aim was providing updated knowledge and performing detailed review about
CB regarding their molecular and biochemical characterization and their clinical utility
in  screening,  diagnosis,  follow-up,  or  therapeutic  stratification for  cancer  patients.
Focusing on conventional, the FDA approved as well as promising future biomarkers in
most common cancers. In addition, emphasizing on their prospective role may be of great
value in  improving the  management  of  cancer  patients.  The challenge and future
prospective of biomarkers, by facilitating the combination of therapeutics with diagnos‐
tics, promise to play an important role in the development of personalized medicine.
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1. Introduction
Increasing cancer burden is a major health problem; GLOBOCAN estimated nearly 8.2 million
deaths and 14.1 million new cancer cases all over the world in 2012 [1] and it is expected to be
16 million new cases every year by 2020 [2]. Widespread application of existing cancer control
knowledge,  early  detection,  appropriate  therapy  with  proper  follow-up,  and  prediction
measures through cancer biomarkers could definitely be very effective tools for the ameliora‐
tion of cancer burden. Biomarkers are “Any measurable diagnostic indicator that is used to
assess the risk or presence of disease” as defined by the US Food and Drugs Administration
(FDA), or they would be comprehensively defined as—“A characteristic that is objectively
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measured and evaluated as an indicator of normal biological processes, pathogenic processes,
or pharmacological responses to therapeutic intervention” [3]. Cancer biomarkers (CB) are
biomolecules produced either by the tumor cells or by other cells of the body in response to the
tumor, and CB could be used as screening/early detection tool of cancer, diagnostic, prognos‐
tic, or predictor for the overall outcome of a patient. Moreover, cancer biomarkers may identify
subpopulations of patients who are most likely to respond to a given therapy [4]. Biomarkers
can be genes, gene products, specific cells, molecules, enzymes, or hormones which can be
detected in blood, urine, tissues, or other body fluid [5].
1.1 Historical background of cancer biomarkers
Two thousand years ago, Ancient Egyptians were the first known who try to find markers for
malignancy as described in an Egyptian papyrus, they had their first attempt in distinguishing
breast cancer from mastitis [6]. Use of CB in medicine then started around 170 years ago, when
Sir Bence Jones described a protein in urine of multiple myeloma patients that could be
identified by its special heat coagulation properties. In 1847, Bence-Jones protein was the first
cancer biomarker that was discovered as a tumor-produced light chain antibody of immuno‐
globulin G (IgG) in multiple myeloma patients, it was excreted in urine in excess and could be
identified by heat denaturation [7]. Later, in 1986, Bence-Jones protein was reported to be
present also in the serum of myeloma patients [8]. Two years later, in 1988, an immunodiag‐
nostic test was approved by the FDA for the detection of Bence-Jones protein which may aid
in the diagnosis of multiple myeloma, Waldenstrom’s macroglobulinemia, leukemia, and
lymphoma. In 1867, amylase was introduced by Sir Michael Foster who reported the increase
levels of serum amylase in patients with cancer pancreas. He suggested urinary amylase as a
biomarker for cancer pancreas. Then, after years of studying pathology and physiology of
pancreas, it was realized that cancer pancreas originate from ductal cells not acinar cell; the
source of amylase enzyme. Therefore, elevation of amylase enzyme may occur in large tumors
impinging on acinar cells [9]. During the next 100 years, numerous studies involved other CB
including hormones as chorionic gonadotropin (hCG) in choriocarcinoma and catecholamines
in pheochromocytoma and neuroblastoma, and enzymes as acid phosphatase in prostate
cancer, and alkaline phosphatase in bone tumors [10]. Definitely, the development of the
immunoassay concept in the 1950s by Yalow and Berson has very important impact on the
field of CB testing using polyclonal antibodies. Later in 1970s, CEA immunoassay was
commercially available. The field of cancer biomarkers showed uprising in 1975 with the
development of monoclonal antibodies and in 1982 with the development of the immune-
metric (sandwich) immunoassay. This leaded to feasible expansion in the introduction of
several immunoassays and new tumor antigens to be used as available tests in routine clinical
practice. Recombinant antibody techniques also provided better understanding of the hy‐
pothesized structure and functions of CB. Recent molecular biology techniques were the key
for discovering and realizing the putative functions of CB as tumor suppresser genes, onco‐
genes, nuclear proteins, and telomerase [11, 12]. Unfortunately, along all these years since the
discovery Bence-Jones protein, only very few CB have been approved by the FDA as diagnostic
or prognostic cancer markers in spite of being extensively studied. However, emerging
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technology of omics, such as genomics and proteomics, may indeed encourage the generation
and Validation of CB [10].
1.2 Cancer development and mechanisms for the production of cancer biomarkers
Cancer is a multifactorial cluster of diseases reflecting fundamental abnormality involving
uncontrolled cell growth and proliferation alternating the normal cell behavior. Molecular
mechanisms exhibit alterations in the expression of multiple genes mostly includes: (proto)
oncogenes, tumor suppressor genes, and DNA repair genes that contribute to the development
of cancer genotype and phenotype with a state of dysregulation of cell proliferation events.
Cancer hallmarks hypothesis has been postulated in 2000 by Hanahan and Weinberg. They
initially categorized biological mechanisms for the cancer development into six processes:
proliferative signaling, avoiding growth suppression, cell death resistance (immortalization),
enabling of replicative immortality, induction of angiogenesis, and finally activation of
invasion and metastasis [13]. Increasing evidence suggest that cancer may be triggered also by
epigenetic changes as histone modification and DNA alteration of methylation causing
alterations in the condensation state of chromatin [14]. Genetic alterations of cancer cells, as
point mutation, gene rearrangement or amplifications, and subsequent disturbances of cell
division and proliferation will be manifested by release of biomarkers of such changes in
majority of patients with a specific type of cancer. Therefore, they can be used as biomarkers
for the cancer detection or predicting responses to various treatments [15–17]. Comprehensive
understanding of the altered molecular mechanisms and cellular processes underlying
carcinogenesis or hallmarks of cancer may link cancer biomarkers and their clinical utility in




cancer patient. Genetic, molecular, and metabolic biomarker may be identified through
applying the sequential of events occurring in cancer cells from gene mutation following its
effects on cellular proliferation and metabolism [18], as illustrated in Figure 1. One of the major
challenges for oncology research is to establish the definite relationship between cancer
biomarkers and cancer pathology, as well as, to detect cancer in early stage beside the devel‐
opment of targeted therapies targeting the exact altered gene or cellular process [16].
1.3 Serum, biological fluid, and tissue Cancer Biomarkers
Understanding mechanisms of carcinogenesis could explain the production and release of CB
in cancerous cells, blood or various body fluid and hence release of those molecules and
elevation during cancer initiation, development, and progression or metastasizing. Mecha‐
nisms for elevation of CB levels in any of the biological fluid could be explained by three
mechanisms. The first mechanism is overexpression or amplification of gene product, or
enhancement of epigenetic changes (affect gene expression) as DNA methylation with release
of such CB as protein human epididymal secretory protein 4 (HE4) in ovarian cancer. HE4 is
overexpressed in ovarian carcinoma and could be also detected in serum [19–21]. However,
clinical evaluation of HE4 revealed that it is also overexpressed in endometrial, breast, and
bronchial adenocarcinoma [22]. The second mechanism of elevation could be typically applied
on serum biomarkers, which is the secretion of cellular proteins or shedding of membrane
proteins. An example of such serum biomarker is alpha-fetoprotein (AFP); an oncofetal protein
with altered single peptide that is elevated in circulation in patient with hepatocellular
carcinoma [23] and HER2-neu, a cell membrane surface-bound tyrosine kinase, released and
elevated in the serum of breast cancer patients after being cleaved by proteolysis. HER2-neu
is also approved by the FDA for monitoring of metastatic cases of breast cancer [24]. The third
mechanism is cell invasion and angiogenesis as occur with prostate-specific antigen (PSA). It
is expressed normally by prostatic epithelium but elevation of PSA levels occurs due to
distorted basement membrane of prostatic cell and lymph angiogenesis [25]. The clinical
application of CB, especially circulating protein targets in cancer management, is emerging
into a new era especially with the availability of promising sensitive techniques that implement
the discovery of “omics” cancer biomarkers in body fluids that may represent a novel, highly
sensitive diagnostic tools for the early detection of cancer. Of even much importance are hidden
cancers that are not easily accessible, for example, nasopharyngeal, ovarian, and pancreatic
cancers. However, there is mandatory need for validation of such biomarkers [26]. CB could
be detected in cancerous cells or tissue of origin in solid tumors, bone marrow, and lymph
node or as circulating cells. CB could be detected in biological body fluid such as serum, ascetic
fluid, pleural fluid, or urine representing noninvasive specimens or samples. CSF fluid is a
suitable candidate for brain and CNS cancer. Meanwhile, urine is one of the promising frontier
for the detection of bladder cancer or for of patients’ surveillance [27]. In addition, it was
postulated that prostate cancer antigen 3 (PCA3) is another promising new molecular marker
for diagnosis and follow-up of cancer prostate [28]. Stool for colorectal cancer, nipple aspirate
fluid, ductal lavage, and cyst fluid for breast cancer are other examples for biological fluid
sources for discovery or clinical application tool for CB [29].
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2. Clinical applications and performance indications of Cancer
Biomarkers
More than 25 years ago, the clinical usefulness of CB was limited to be an effective tool for
patient’s prognosis, surveillance, and therapy monitoring. Definition of tumor markers that
have been adopted by the fifth International Conference on Human Tumor Markers held in
Stockholm, Sweden, in 1988 stated that “Biochemical tumor markers are substances developed in
tumor cells and secreted into body fluids in which they can be quantitated by non-invasive analyses.
Because of a correlation between marker concentration and active tumor mass, tumor markers are useful
in the management of cancer patients. Markers, which are available for most cancer cases, are additional,
valuable tools in patient prognosis, surveillance, and therapy monitoring, whereas they are presently
not applicable for screening. Sero-diagnostic measurements of markers should emphasize relative trends
instead of absolute values and cut-off levels.” However, CB have been reported to be used also for
screening of general population or risk groups, for differential diagnosis, and for clinical
staging or stratification of cancer patients. Additionally, CB are used to estimate tumor burden
and to substitute for a clinical endpoint and/or to measure clinical benefit, harm or lack of
benefit, or harm [4, 18, 30]. Among commonly utilized biomarkers in clinical practice are PSA,
AFP, CA125, and CEA. PSA is one of the serum biomarker currently used consistently in
primary care to assess the risk of underlying prostate cancer. Cancer antigen 125 (CA-125) can
be a biomarker of ovarian cancer risk or an indicator of malignancy, but it has low sensitivity
and specificity. CEA is another biomarker that is elevated in patients with colorectal, breast,
lung, or pancreatic cancer [31]. A major challenge is to develop promising CB for the stratifi‐
cation of cancer patients not only to predict outcome or response for therapy, providing
customized treatment, but also for personalized therapeutic strategies of cancer patients.
Among promising biomarkers in that field is survivin and HER2-neu [32, 33].
2.1. Sensitivity and specificity for evaluation of accuracy of CB
As being released from tumor cells, or body cells in response to the tumor, CB can be detected
in any of the body fluids, secretions, or tumor tissue and cells. CB can be detected in serum,
plasma, or whole blood, also in whole excretions as urine, sputum, or CSF. Therefore, CB could
be assessed in noninvasive and in serial manner. Evaluation of cancer biomarker in tissue or
cells requires tissue biopsy or more invasive technique than serum biomarkers. CB can be
detected in tissues by special techniques but in an invasive manner than serum or urine
biomarkers. Genetic biomarkers could be detected in DNA derived from tumor tissue, whole
blood, or buccal mucosa cells [34]. Evaluation of diagnostic value of any test or marker is
usually performed with referral to the terms of sensitivity and specificity of that marker.
Specificity means that ability of the marker to detect non-diseased subjects whereas sensitivity
refers to the ability of that test to identify diseased subjects (patients) [35]. At definitive cutoff
value, a test or biomarker may be found above that value (positive), but actually not all
positives are diseased subjects. Therefore, sensitivity is calculated, as the ratio of the all
positives who are found by that test, above the cutoff value to the total number of abnormals




Similarly, by applying the same cutoff value for the same test, some people with normal results
below cutoff value are actually normal (true negative) but not all of them are not having the
disease (false negative). Therefore, the true negative rate or specificity could be calculated as
the ratio of the all negatives who found by the test below cutoff value to the total number of
normals known not to have the disease (true negative) [36]. Therefore, a CB with 100%
specificity could be used to correctly identifies all non-cancerous subjects, CB with 70%
specificity could identify only 70% of the non-cancerous as being negative (true negatives),
and however, 30% of non-cancerous are falsely identified positive (false positives) [37].
Supposing sensitivity of a CB is 100%, this means that it could identify all cancer patients and
if another CB supposed to be with 90% sensitivity, it could detects 90% of patients with cancer
(true positives) but fail to detect it only in 10% of cancer patients (false negatives). Conse‐
quently, sensitivity and specificity could be computed across all possible cutoff or threshold
values and both are inversely related to each other [38].
Figure 2. Cancer biomarker range of results among cancer and non-cancerous patients.
2.2. Receiver operating characteristics (ROC) curve analysis
Comparative analysis of different sensitivities and specificities at different thresholds would
be very effective to judge the accuracy of diagnostic test. ROC curve was introduced by the
British during World War II in order to identify accurate radar detectors and was used later
in performance evaluation of radiological tests [39]. ROC curve is simply defined as perform‐
ance indicator of a test or biomarker by plotting its sensitivity along the y axis and its 1-
specificity or FPR (false positive rate) along the x axis to assess the diagnostic ability of such
biomarker and in discrimination of the diseased from the healthy subjects [40]. ROC curves
have been extensively used for evaluation of the accuracy of diagnostic tests with meaningful
interpretations. Several indices could be derived from it such as the area under the curve (AUC)
that determines the average of the sensitivity values for all possible specificity values and
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includes whole area underneath the entire ROC curve [36]. AUC could have a range between
one and zero because values of the x and y axes probably having values ranging from zero to
one as well. The closer the value of AUC to one the better is the clinical performance of that
test [40]. Comparing AUC areas of different tests can be used to compare their diagnostic
performance as AUC is a measure of their overall performance. The test with bigger AUC value
is of better overall performance. On comparison of two tests and if both AUC areas are equal,
this indicates same diagnostic performance of both tests, but non-necessarily mean identical
ROC curves [41]. Figure 2 represents the CB levels among cancer and non-cancer cases, while
Figure 3 illustrates ROC curve and area under the curve.
Figure 3. ROC curve analysis and comparison of area under the curve.
2.3. Ideal biomarker
Measurement of sensitivity and specificity of a biomarker at a range of cutoff values could be
of an important impact for evaluation of CB as we may chose a definitive cutoff value that
achieves the highest sensitivity and specificity. Increment of cutoff point will definitely lead
to increase of specificity of the test or false negative patients but on the other hand, this will
decrease number of false positives; this indicate a highly specific but low sensitive biomarker.
Similarly, if the cutoff point is low that indicates a highly sensitive but low-specific biomarker,
as there are fewer false negatives but more false positive subjects. Indeed, pairs of sensitivities
and specificities may describe accuracy of the biomarker and its ability to discriminate between
healthy (normal) and diseased. We can identify the threshold limit or cutoff value to a
diagnostic sensitivity of 100% or less but considering the corresponding specificity for that




assessment of accuracy. Indeed assessment for performance at definitive point may be
misleading or this may results in bias for comparison between tests [42]. Ideal biomarker must
be strictly able to differentiate between cancerous from benign cases, aggressive tumors from
insignificant one; it should be of high specificity and sensitivity. Furthermore, it should be a
noninvasive and inexpensive [30, 43]. The characteristic features of an ideal biomarker are
variable and relay to some extent on the application and classification of CB. Mostly, CB have
to fulfill the following general properties to be considered ideal. Obviously, no biomarker
could meet these requirements all together, but these criteria should be highly considered for
selection of diagnostic biomarker [44]:
• High clinical sensitivity: produced by all patients with that specific cancer (100% TPR).
• High clinical specificity: low false negative rate (100%True negative).
• Organ or tissue specific.
• Proportional to tumor burden or volume: quantitatively proportionate to tumor volume or
disease progression.
• Short half-life: reflecting quickly any early changes in tumor burden for proper monitoring
of therapy.
• Present (if any) at low levels in the serum of healthy individuals and those with benign
disease.
• Sharply discriminating metastasis.
• Exist in quantitative, standardized, reproducible, and validated assay.
• Inexpensive or low coasting method.
• Obtained in a noninvasive manner: detected in serum, body fluids, or in easily accessible
tissue.
3. Uses, clinical utility, and limitations of CB
Conventionally used tumor markers or CB may be either proteins or glycoproteins, being
probably not involved in carcinogenesis or development of cancer process, rather are likely to
be by-products of malignant transformation. Low molecular weight, small molecules or
nucleic acids markers (as gene mutations or polymorphisms and quantitative gene expression
analysis, peptides, proteins, lipids metabolites, and other small molecules are promising and
recently being evaluated as potential clinically useful tumor markers, the patterns of gene
expression and genetic alterations and defects may be the framework of the molecular
classification of CB [11]. There are several classification s for CB depending on different aspects
related to their chemical nature, proposed mechanisms for their release and applications. Six
years ago, a unique classification proposed by Mishra and Verma [45] with an emphasis on
clinical utility of CB. They classified CB into prediction biomarkers as DNA biomolecules,
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detection biomarkers as RNA molecules, diagnostic biomarkers as protein biomarkers, and
prognosis biomarkers as glyco-biomarkers. Clinical applications and uses of CB, as simply
illustrated in Figure 4 are screening and early detection, diagnostic confirmation, prognosis
and prediction of therapeutic response, and monitoring disease and recurrence [46]. Another
use of CB includes cancer susceptibility and risk assessment markers which include the
identification of individuals who are at a high risk of developing cancer or candidates for
screening programs and early preventive studies [47]. Risk or susceptibility assessment
markers include markers of inflammation, oxidative stress and single-nucleotide polymor‐
phisms (SNPs), and mutations in certain genes [48, 49]. Table 1 illustrates most of traditional,
the FDA approved, and clinically relevant CB with their uses in various cancer types.
           Figure 4. Clinical utility and uses of cancer biomarkers.
3.1. Screening/early detection
In 2008, Wald defined screening as “the systematic application of a test to identify subjects at
sufficient risk of a specific disorder to benefit from further investigation or direct preventive
action, among persons who have not sought medical attention on account of symptoms of that
disorder” [50]. Earlier efficient treatment must lead to better outcome compared with the
treatment available at later cancer stages or symptomatic patients. Screening aim was to detect
disease when subjects are asymptomatic which differ from diagnosis of symptomatic patients.




outcome state and even before appearance of symptoms. Reports calculated a drop in the 5
years survival rate from being about 90%, in early localized breast cancer, to reach about 60%
in local metastasizing and only 30% to distant metastasizing cases of breast cancer [51].
Therefore, screening CB should be able to detect cancer in an early stage or asymptomatic stage
and consequently will result in increase of survival rate and decrease complications or
morbidities. Screening test must be highly specific to minimize false positives as less as
possible. High specificity is mandatory for screening biomarker because even a small false-
positive rate could result in large number of unnecessary other invasive diagnostic procedures
that may be unneeded with the associated psychological burden and excess costs. Ideal
screening programs have to be noninvasive and inexpensive and definitely lead to obvious
reduction in morbidity and mortality and increase in survival rate. Usually, screening
programs are directed for highly prevalent cancers and further treatment and follow-up are
mandatory [34]. Other limiting factors for screening biomarker are the low diagnostic sensi‐
tivity and specificity of most of the currently used biomarkers to serve as screening markers
and being elevated later in the course of cancer. However, few biomarkers have been used as
screening biomarkers as AFP in screening for hepatocellular cancer in high‐risk subjects, PSA
in screening for prostate cancer, CA125 in screening for ovarian cancer, and fecal occult blood
testing (FOBT) in screening for colorectal cancers (CRC) and vanillymandelic acid (VMA) in
screening for neuroblastoma in newborns [52]. PSA was cleared by the FDA as a screening
Cancer biomarker Organ specificity/cancer type Application/uses References
Prostate-specific antigen (PSA) Prostate/BPH Screening, diagnosis and monitoring [86, 133]
Carbohydrate antigen 125 (CA125) Ovarian Diagnosis, prognosis, detecting
recurrence and monitoring therapy
[134]
Carcinoembryonic antigen (CEA) Colorectal/hepatic Monitoring therapy [135–137]
Prognosis
Detecting recurrence
Screening for hepatic metastases
Carbohydrate antigen 15.3 (CA 15-3) Breast Monitoring therapy [69, 138]
Estrogen, progesterone receptors
(ER and PgR)
Breast Stratification/select patients for endocrine therapy [139–141]
HER2 Breast Monitoring trastuzumab therapy [18, 32, 33, 142]







Alfa-fetoprotein Hepatocellular carcinoma Diagnosis [144–146]
Detecting recurrence
Monitoring therapy
Calcitonin Medullary carcinoma of thyroid Diagnosis and monitoring therapy [147, 148]
Thyroglobulin Thyroid Monitoring [149]
CA 19-9 Pancreatic Monitoring therapy [76]
Nuclear matrix protein 22 (NMP-22) Bladder Screening, monitoring and prognosis [150]
Prostate cancer antigen 3 (PCA3) Prostate Prognostic [151]
Table 1. Current cancer biomarkers and uses in clinical practice.
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biomarker for prostate cancer; however, false positive elevation of PSA levels can be found in
individuals with benign or inflammatory conditions as benign prostatic hyperplasia and
prostatitis [53]. Contribution of PSA screening in decreasing mortality is still being a matter of
contraverse [54, 55].
3.2. Diagnosis/differential diagnosis
A diagnostic biomarker would be applied only for symptomatic patients in contrast to
screening biomarker that would be applicable only for symptomatic individuals. Interestingly,
the characteristics of an ideal diagnostic biomarker are similar to the characteristics for
screening. Notably, most of well-established biomarkers for screening could be used as
diagnostic markers and PSA is well-recognized example. PSA, in combination with a digital
rectal examination (DRE), is the most commonly used diagnostic tool for prostate cancer [56].
Regarding encountered limitations for diagnostic biomarkers, current available cancer
biomarkers are still having low diagnostic sensitivity and specificity; however, diagnostic
biomarkers must be of high sensitivity in order to be a good diagnostic biomarker [57]. For
example, Bence-Jones protein in urine remains one of the strongest, well-established diagnostic
indicators of multiple myeloma [29]. Nevertheless, some CB have proved to be useful in
confirming diagnosis, often in conjunction with a panel of other markers especially to identify
primary tumor in metastatic cases with unknown primary and/or other clinical, imaging tools
[58]. Use of panel of CB in order to increase sensitivity and specificity of CB in diagnosis has
been used to confirm diagnosis of certain cancers. In 2005, Mor et al. [59] reported that a panel,
consisting of 4 biomarkers: leptin, osteopontin, prolactin, and insulin-like growth factor 2,
collectively had a sensitivity of 95% and a specificity of 95% for the detection of ovarian cancer.
In another report, addition of two biomarkers to the previously studied panel included
macrophage inhibitory factor and CA125, sensitivity was 95% and a specificity increase to
99.4% for the detection of ovarian cancer. Other attempts to improve diagnostic sensitivity and
specificity included combination of CA125 with ultrasonography for diagnosis of ovarian
cancer [60].
3.3. Prognosis/prediction
Prognosis is the probability of cure or likely outcome of any patient. A prognostic marker is a
disease or patient characteristic feature at the time of diagnosis independent upon therapy;
hence, prognostic marker will provide information about the natural history of the disease or
the likely outcome. Meanwhile, a predictive biomarker predicts the response to different
therapeutic modalities; hence, predictive biomarker is the basic concept for personalized
medicine [57]. Magnitude of elevation or levels of CB usually reflects tumor burden, or mass
hence higher elevation of CB level mostly reflects bad prognosis and vice versa. By reflecting
the tumor burden, CB can be used in staging system for cancer or the tumor–node–metastasis
(TNM) classification. For example, in testicular germ cell tumors, very high levels of a CB such
as AFP, LDH, and HCG-β may indicate an aggressive cancer with poor prognosis and outcome
so such biomarkers may be used for staging in TNMS system in place with a site-specific




staging of lymphoma as well [62]. However, the accuracy of the marker in determining tumor
stage is poor. Estrogen receptor (ER) is one of the widely used prognostic and predictive tissue
biomarker; as a predictive tissue biomarker, ER is used for selecting the patients likely to
respond to hormonal therapy. Therefore, patients with ER positive tumors will mostly respond
to selective ER modulators or aromatase inhibitors independent upon stage of breast cancer
weather early or advanced [63]. ER is considered a prognostic marker as well, once ER is
negative, that indicate a poor prognosis and when positive a good prognosis is likely the
outcome for such patients. In spite of most of CB have some prognostic values which their
specific therapeutic impact cannot be applied because of their poor predication accuracy [64].
In the same context, high serum levels of HER2 in serum of breast cancer patients correlate
with poor prognosis in such patients [24]. Targeted therapy for HER-2 positive breast cancer
patients, trastuzumab (Herceptin), is a recombinant monoclonal antibody against HER-2.
Herceptin has been used in women with metastatic breast cancer that overexpressed HER2
and reported to increases the clinical benefit of first-line chemotherapy in those patients [65].
KRAS is a predictive biomarker for colorectal cancer, because patients with somatic mutations
in KRAS have poor response to anti-epidermal growth factor receptor (EGFR)-targeting
therapies [66].
3.4. Therapeutic monitoring/follow-up/evidence of metastasis or recurrence
Therapeutic monitoring may constitute the most common applications of CB markers in
clinical practice [67]. Clinically useful biomarkers usually fluctuate in accordance with tumor
behavior, size, or burden changes that are best elicited by increase in levels of CB with
progressive disease, decrease with remission, and do not change significantly with stable
disease. Kinetics of CB are more important than single measurement or elevated values [68].
Recurrence of cancer may be detected biochemically via rise in CB levels even before appear‐
ance of any clinical or radiological evidence of cancer recurrence. Continues follow-up for
cancer patients during and after therapy can mirror their condition if the levels of CB were not
elevated or remain at basal level, indicating successful therapy or remission. On the other hand,
rising of CB level above the basal level indicates recurrence of the disease. CB can be a warning
sign of recurrence earlier by 3–12 months before any other diagnostic methods. Many CB could
be used for monitoring therapy or detection of recurrence or metastasis, for example, CEA in
colorectal cancers, cancer antigen 125 (CA 125) in ovarian cancers, or PSA in prostatic cancer
[69]. Some patients who encountered resistance to therapeutic modalities will experience
increasing levels of CB, and in that case, reconsideration of alternative therapy is mandatory.
Monitoring CB, as screening and diagnostic biomarker needs to be both diagnostically
sensitive and specific to ensure proper assessment of effective therapy and continuation of
such beneficial therapies and early discontinuation/replacement of ineffective therapy or
resistant cancer to those therapies. A representing example of monitoring CB is carbohydrate
antigen 19-9 (CA19-9) which has been used in pancreatic in CRC [70]. CA19-9 has been
approved by the FDA in 2002 as a monitoring marker for pancreatic cancer. However, it is not
recommended as a screening biomarker [71, 72]. Monitoring biomarkers have been extensively
used in clinical practice with few limitations perhaps related to detectors’ biomarkers of
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recurrence rather than monitoring ones. Limitations of those biomarkers probably related to
short lead time and poor affection to the outcome [29].
4. Applications of CB in most common cancers
Cancer is an enormous health problem all over the world, over years cancer was indicated as
one of the leading causes of death among males and females; an estimated 8.2 million deaths
among cancer patients occurred in 2012 worldwide [73]. Over 11 million patients are diagnosed
with cancer every year, and 16 million new cases will be expected yearly by 2020 [2]. According
to the latest report of the International Agency for Research on Cancer (IARC), the GLOBO‐
CAN worldwide estimates of cancer incidence and mortality published on 2015 and the most
common cancers’ types among males were lung, prostate, colorectal, liver, and urinary
bladder. Meanwhile, breast cancer, lung, liver, ovarian cancers were among the most common
cancers in females worldwide [1]. For many years ago, few CB have been used as an effective
tool in clinical practice, while also promising CB were extensively studied for their clinical
utility. As previously discussed, traditionally used or promising CB may be used for risk
assessment for cancer, screening among asymptomatic population, confirming diagnosis or
differentially discriminate benign from malignant, prediction of outcome or prognosis, and
monitoring of therapy or staging of cancer applications [58].
4.1. Breast cancer
Breast cancer is the most common malignancy among females and the first leading cause of
cancer mortality worldwide; its prevalence is surprisingly increasing at a rapid rate lately [74].
Therefore, it is critical to use all available tools for early diagnosis and proper management of
cases. Clinically, symptoms are mainly breast lump, nipple discharge, or skin or nipple
changes. Screening guidelines by The American Cancer Society recommend that women over
40 have to perform mammography and a yearly or every other year clinical breast exam [75].
Diagnosis mainly relies on pathological examination; however, the role of CB in breast cancer
is mainly helpful with prognosis, monitoring of therapy, and for follow-up. Notably, CB does
not show great utility for early diagnosis [76]. Assessment of ER and progesterone receptors
(PR) in tissue for newly diagnosed breast cancers has been recommended by European Society
of Medical Oncology, for predicting response to hormone therapy in early and advanced breast
cancer cases [63, 77, 78]. HER-2 is another prognostic marker, most useful for selecting patients
with either early or metastatic breast cancer for the treatment with Trastuzumab (Herceptin)
[79] or predicting resistance to tamoxifen therapy in early stage of breast cancer [63]. Deter‐
mination of risk groups for the development of breast cancer, who must be included in
screening program, involves the detection of genetic mutation of BRCA 1 or BRCA 2 genes,
which account for up to 5% of breast cancer cases. Due to their high susceptibility to breast
and ovarian cancer, it is strongly recommended that women carrying BRCA1 or BRCA2
mutations undergo routine cancer screening [80]. It was reported that low levels of urokinase
plasminogen activator (uPA) and plasminogen activator inhibitor-1 (PAI-1) correlate with a




factors of newly diagnosed lymph node-negative breast cancers [81, 82]. Serum biomarkers
are mainly applicable as monitoring markers during therapy or to less extent prognostic
markers and usually assisted in post-operative surveillance, and CB included under that
category include CA15.3, CEA, and BR 27-29 [83, 84]. They are used in conjugation with other
tools of radiological and clinical assessments to monitor chemotherapy in advanced breast
cancer cases. Elevation of serum levels of these markers may indicate recurrence or progression
of the disease [85].
4.2. Prostate cancer
Prostate cancer (PCa) is one of the most common cancer in men and most common causes of
male cancer-related deaths [74]. Strong evidences suggested that PSA test revolutionized the
prostate cancer screening and diagnosis landscape, and the introduction of PSA as a screening
test has led to a sharp increase in the incidence of prostate cancer because there has been a shift
to diagnosis at earlier stages, consequently reducing mortality from prostate cancer [86]. Later,
many studies demonstrated significant improvement sensitivity of PSA as a diagnostic marker
using a PSA subtractions and isoforms [−2] (proPSA) and its percentage derivative % proPSA
(percent value relative to PSA) as these fraction may help for the discrimination between
benign and malignant prostatic tumors in patients with PSA values ranging from 4 to 10
μg/L [87, 88]. Other novel and promising biomarkers under investigation include human
kallikrein type 2, prostate cancer antigen 3 (PSA 3), and prostate stem cell antigen (PSCA) [89].
PCA3 urine assay has promising role in improving the accuracy of diagnosis in prostate cancer
[90]. Elevated levels of metalloproteinase 2 and 9 (MMP-2 and MMP-9) members of protease
family have been associated with prostate cancer diagnosis [91]. MMPs have been studied as
biomarkers of therapeutic monitoring in prostate cancer [92].
4.3. Ovarian cancer
Most of the patients with epithelial ovarian cancer are diagnosed late and they have clinically
advanced stage III and IV on diagnosis; therefore, ovarian cancer needs a sensitive and specific
diagnostic biomarkers [93]. CA 125 is one of the most widely and conventionally used CB. It
is recommended as a screening biomarker for women who have positive family history or are
high risk for the development of ovarian cancer, beside CA125 has been used in conjugation
with vaginal ultrasound as a well-established, diagnostic biomarker [94]. CA125 is also been
used as monitoring biomarker, being decreased after starting of chemotherapy or surgery, that
correlates with favorable response basal level of CA125, two weeks before starting any
therapeutic intervention then follow ups and continues monitoring of its level at regular
intervals are highly recommended [95]. Other biomarkers were extensively studied in
monitoring of ovarian cancer and in prediction of prognosis but further studies are needed for
proper confirmation of their exact role. This panel includes kallikreins (5–9), osteopontin,
Her-2/neu, tumor-associated inhibin, CEA, trypsin inhibitor, hCG, interleukin-6 (IL-6),
prostasin, TPA, lysophosphatidic acid, plasminogen activator inhibitor-1 (PAI-1) [95–97].
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4.4. Colorectal cancer
CRC is ranked third among all cancers all over the world. An estimated one million new cases
are diagnosed and half of a million cases died each year [1]. The most common site for colorectal
carcinoma is the rectum encountering 38% of all cases followed by sigmoid accounting 29% of
cases [98]. Screening program for CRC should be directed to all asymptomatic individuals
above 50 years as recommended [99]. National Academy of Clinical Biochemistry (NACB)
recommends that all subjects 50 years or older should undergo screening for colorectal cancer.
Multiple screening procedures exist [100]. Fecal occult blood test (FOBT) is the most widely
used CB in stool [101]. Testing for blood in the stools involves either detecting globin fraction
of blood (hemoglobin) by fecal immunochemical test or the guaiac test which measures
pseudo-peroxidase activity of heme fraction of hemoglobin. CEA was characterized and
introduced into clinical practice in 1965 [76]. It is widely used as universal or non-organ, non-
tissue-specific tumor marker. CEA is not used in screening of CRC due to its low sensitivity
and specificity, beside the low prevalence of CRC among asymptomatic population; however,
it is very efficient prognostic and therapy monitoring biomarker [102]. CEA estimation is
recommended at the beginning of therapy then every 1–3 months all through the therapeutic
regimen, it is also the marker of choice for metastatic cases of CRC [103]. CA19-9 has been used
as prognostic marker, in surveillance of CRC after surgical resection and as monitoring marker
for therapeutic intervention in advanced cases [104]. Other CB under investigation are CA242
and tissue inhibitor of metalloproteinases type 1(TIMP-1) and both may complement CEA in
the surveillance of patients with colorectal cancer [105].
5. Discovery of new biomarkers/validation/technologies (omics)
Among hundreds of thousands of cancer biomarkers have been discovered, only few of them
have been approved during the past two decades by the FDA for monitoring response,
surveillance, or recurrence of cancer [106]. To be a clinically applicable and reliable biomarker,
it must be of value for informing clinical decision-making to improve the patient outcome
[107]. Initially, CB have to distinguish between people with cancer and those without. In fact,
many biomarkers do not achieve beyond this point because the investigators are either unable
to develop robust, accurate assay methods, or this biomarker lacks sufficient sensitivity
and/or specificity [108]. Actually, there was very low rate (0.1%) of successful clinical transla‐
tion of biomarker [109]. Developing new cancer biomarkers has been formulated in stepwise
manner. About 15 years ago, Hammond and Taube proposed an approach for CB development
starting from discovering the marker, developing an assay method for assessment, analyzing
its clinical potential preliminarily, standardization of its assay, and finally validation of such
biomarker for clinical use [110]. Structured phased model for the development evaluation, and
validation of biomarkers, (shown in Table 2) has been proposed by Pepe et al. [111] and has
been adopted and modified by others [112, 113]. This model was similar to another model
commonly used in drug development strategy including five phases: preclinical exploratory
studies, clinical assay and validation, retrospective longitudinal repository studies, prospec‐




analytical validation step concerned mainly with testing and assay methods of the biomarker
(technical aspects). After that, the biomarker has to be analyzed for its clinical validity for
discriminating between groups independently. Finally, candidate biomarker must be assessed
for clinical utility for providing additional input for patient management or aid to provide
additional information helping in decision-making for patients in order to improve patient
outcome [114].
Phases Type of studies Outcome
Phase I Preclinical exploration Promising directions are explored and potential
biomarkers identified
Phase II Clinical assay and validation Determination of the potential capacity of the biomarker
to established disease
Phase III Retrospective longitudinal Determine how well biomarkers detect preclinical disease through
retrospectively testing
Phase IV Prospective screening Identify the characteristics of the disease detected by the biomarker
and determine the false positive rate
Phase V Cancer control Quantification of the role of the biomarkers in the
reduction of disease burden through Phase 5
population screening
Table 2. Structured phased model for the development evaluation, and validation of biomarkers modified from Pepe
et al. [111] and Paradiso et al. [113].
5.1. Challenges for discovery of novel biomarkers
Development of biomarkers for cancer screening, early detection, and monitoring of treatment
has both biological and economic challenges. Most detection methods currently in use identify
mostly late stage or fully developed cancer, not in the premalignant or early lesions, which are
amenable to resection and cure. In spite of the fact that a screening test might detect cancer at
the preclinical stage, at the same time, not applicable for follow-up so it could fail to detect
micrometastasis, therefore limiting the benefit of early detection and treatment [115]. Another
challenge is that in many organs, for example; prostate or colon, preneoplastic lesions are much
more common than aggressive cancers [116]. This creates the question of whether any
screening method should just focus on early lesions or whether it should also analyze the
behavior of the tumor. Another challenge for the development of CB is the nature of the cancer
as being a heterogeneous disease; it is composed of many biologically different phenotypes
with different responses to intervention. The nature of its heterogeneity is found between cells
of a single macroscopic cancer. This heterogeneity may complicate the development of
biomarkers. Therefore, the development of biomarker by genomic and proteomic means might
carefully address the heterogeneity issues [117]. Detailed and comprehensive knowledge of
cancer at the cellular and molecular levels has grown dramatically and exponentially in the
past two decades and has resulted in significant improvement in the characterization of human
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tumors which in turn has catalyzed a shift toward the development of targeted therapies, the
basic concept for personalized medicine [118]. Therefore, it has been recently postulated that
the emergence of highly powerful “omics” technologies, such as genomics, epigenomics,
transcriptomics, proteomics, and metabolomics [119]. Omics technologies may be the back‐
bone toward the discovery of novel CB and/or panels, with distinct advantages over the
currently used biomarkers. Omics have increased the number of potentially investigated
biomarkers as DNA, RNA, or other protein biomolecules. The former concept of single
biomarker discovery was replaced recently by multi-biomarkers discovery of panel of genes
or proteins whereby, rising the query of whether the heterogeneous and multifactorial cancer
may have single fingerprint.
5.2. Genomic technologies
Genomic technologies have been used extensively for the characterization of cancers at the
molecular level hence providing better comprehensive understanding of cancer and may
provide scientists the basic concepts for designing drugs that could target specific molecules
or the fundamental of personalized medicine [120]. Personalized medicine has been defined
by The US National Cancer Institute (NCI) as “a form of medicine that uses information about a
person’s genes, proteins, and environment to prevent, diagnose, and treat disease.” [50]. Genomic
alterations that may be associated with cancer include gene amplification, mutation, chromo‐
somal rearrangements, and aberrant methylation. Molecular alterations are evolved in the
content or sequence of DNA, its transcriptions mRNA or microRNA, the production of
proteins, or the synthesis of various metabolites. Genomic alterations can be assessed through
genome sequencing technologies or microarray for gene expression [29]. Mutation screening
can be assessed by sequencing technique, while assessment of DNA copy numbers could be
analyzed by DNA microarrays and DNA expression profile via PCR [120]. Genomic microar‐
rays represent a highly powerful and sensitive technique; it can predict the clinical behavior
of tumors [121]. Genomics has been extensively used for biomarker discovery and identifica‐
tion. Human genome accounts approximately 30,000 genes, the availability of omics techni‐
ques allows researchers to move another step further, which is designing and manufacturing
of a biological drug with better understanding of pharmacogenomics, thus biomarkers allow
the studying of the influence of genetic variation, providing new methods for treating patients
on an individual basis. The outcome of such researches is known as personalized medicine
[122].
5.3. Epigenomics
Epigenetics refers to heritable changes in gene expression that are not attributable to alterations
in the sequence of DNA. Epigenetic changes include DNA methylation, histone modifications,
and non-coding RNAs. These alterations may be present ubiquitously human malignancies
and may appear in early cancer development. Therefore, they provide particularly attractive
markers with broad applications in diagnostics [123]. Methylated DNA (meDNA) is a various




progression. In fact, the inherent stability of DNA is one of the major advantages of detecting
methylation. Genes that are often methylated in tumors are termed tumor biomarkers because
their methylation can be used to detect the disease. Utilization of meDNA markers is superior
comparing to other types of tumor biomarkers for numerous reasons including: The analysis
of DNA methylation can be achieved with a wide range of methods using different types of
biological material such as tissue, plasma, serum, sputum, and urine, among others [124].
Methodology of DNA methylation measurement has progressed gradually through the years.
Assessment techniques for epigenetic changes may include: The bisulphate conversion of DNA
followed by PCR amplification allows gene-specific methylation analysis (methylation-
specific PCR, i.e., MSP), which is based on using primers and probes specific to the corre‐
sponding methylated DNA sequence [125]. This technology makes the detection of hundreds
of thousands of DNA methylation signals a reality. These signals can be digitized into a long
string of ones and zeros, creating a digital phenotype that reflects genetic activity in a particular
cell or tissue, that is, whether it is functioning normally or whether it is abnormal. Around 200
such biomarkers have been discovered through a large-scale genome-wide screening effort of
all major human tumors for DNA methylation biomarkers in bio-specimen; tissue and serum
[126].
5.4. Proteomics
Proteomics-based strategy diseases identification is considered as one of the dynamic and
innovative tools that could confirm, complement, or quite often supply more elaborate
information beyond that obtained by other high-throughput approaches such as genomic,
transcriptomics, and epigenomics. Despite genomic expression profiling is a highly reliable
method for cancer classification and prognostication [127, 128]. The function of such genes and
the data interpretation in the context of functional networks require their translation into active
proteins and their analysis through the power of proteomics. Moreover, although studies
focusing on detecting the differential expression of mRNA have been extremely informative,
they do not necessarily correlate with the functional protein concentrations. Therefore, post
genomic “proteomic” projects correlating protein expression profiles to cancer are essential
for a complementary and comprehensive representation of cancer biology. Moreover, target‐
ing-specific protein pathways involved in tumorigenesis present a realistic aim in cancer
treatment, as proteins exert their effects through specific pathways rather than functioning
individually [120]. Macromolecules, in general, and proteins, in particular, are highly dynamic
molecules. Mechanistically, proteins can be subjected to extensive functional regulation by
various processes such as proteolytic degradation, posttranslational modification, involve‐
ment in complex structures, and compartmentalization. Proteomics is concerned with
studying the whole protein repertoire of a defined entity in a biological fluid, an organelle, a
cell, a tissue, an organ, a system, or the whole organism. Therefore, in-depth studying of
proteomics profiles of various bio-specimens obtained from cancer patients is expected to
increase our understanding of tumor pathogenesis, monitoring, and the identification of novel
targets for cancer therapy. In a simple way, proteins may be actively secreted or released by
the tumor cells as a result of necrosis or apoptosis and released into the circulation [76]. This
Role of Biomarkers in Medicine18
changes the protein profile. The difference in signal intensities may be detected by comparison
with sera from normal individuals. Secretomics, a subfield of proteomics that studies secreted
proteins and secretion pathways using proteomic approaches, has recently emerged as an
important tool for the discovery of biomarkers. In what is now commonly referred to as
proteogenomics, and proteomic technologies are further used for improving gene annotations.
Parallel analysis of the genome and the proteome facilitates discovery of post-translational
modifications and proteolytic events (comparative proteogenomics).
5.5. Metabolomics
A cancer biomarker can be a metabolite, secreted by tumor, metabolic pathway or process, and
may be employed to diagnose cancer and predict patient response towards therapies and
monitor recurrence. Though proteins are the key tumor markers that can be as diverse as
molecular, biochemical, physiological, or anatomical [129]. Markers can be utilized for
diagnosis (to identify early stage), prognosis (assess the lethality), and prediction (of patient’s
response to treatment) of cancer. The markers can be detected in body fluids (blood, urine,
serum, stool, saliva), or tissues (tissue samples or biopsies of the cancer). Moreover, it has been
shown recently that cancer volatile organic compounds (VOC) markers can be detected in
breath [130]. However, detecting the markers is a sophisticated process and metabolomics is
one of the omic technologies. Among genome, transcriptome, proteome, and metabolome, the
latter is the powerful representative of the phenotype [131]. Exploring the cancer metabolome
seems to be an effective way to study the phenotypic changes associated with tumor. Screening
biomarkers by recruiting an array of analytical techniques has been emphasized [132]. Rather
than a single metabolite, a pattern is believed to be more indicative of cancer status. Metabo‐
lomic approach makes it feasible to detect an array of metabolites in a single assay. The
principal analytical tools employed for metabolome analysis are mass spectrometry (MS) and
nuclear magnetic resonance spectroscopy (NMR).
6. Conclusion and prospective
Cancer biomarkers play an important role in the field of oncology and in clinical practice for
risk assessment, screening, diagnosis integrated with other diagnostic tools and mostly for the
determination of prognosis and response to treatment and/or relapse. Cancer biomarkers can
also facilitate the molecular definition of cancer. It is necessary for clinicians and researchers
to have a comprehensive understanding of molecular aspects, clinical utility, and reliability of
biomarkers in order to determine whether and in what setting a biomarker is clinically useful
for the patient care, or additional evaluation is required before integration into routine medical
practice. The challenge and future prospective of biomarkers, by facilitating the combination
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